Obesity treatment is evolving in Portugal with the introduction of Wegovy tablets, marking a significant shift from injectable medications. This development is a game-changer for patients, offering a more convenient and potentially more accessible treatment option. The oral treatment, already approved by the European Medicines Agency (EMA), presents a promising alternative to the current injectable versions available in Portugal. With dosages ranging from 1.5 mg to 25 mg, the tablets provide a flexible and patient-friendly approach to managing obesity. The gradual increase in dosage, starting at 1.5 mg and building up to 25 mg over four weeks, ensures a controlled and safe treatment process. This methodical approach is a key advantage of the oral treatment, allowing for a more personalized and effective journey towards weight management.
The arrival of Wegovy tablets in Portugal is a significant step forward in the fight against obesity, offering a more convenient and potentially more affordable treatment option. The Danish pharmaceutical company Novo Nordisk, which owns Wegovy, has taken steps to lower medication prices, making obesity treatment more accessible. This move is particularly important as obesity is considered a chronic disease requiring long-term treatment. By reducing prices by 19%, Novo Nordisk is making a significant contribution to improving access to obesity treatment in Portugal. The oral treatment is already available in the United States, the United Kingdom, and the United Arab Emirates, and its introduction in Portugal is a positive development for patients seeking effective and convenient weight management solutions.
The oral treatment of Wegovy also brings a new injectable version to the market, a pre-filled single-use pen containing 7.2 mg of the medication. This new product is expected to enter the Portuguese market in the coming months, offering patients a choice between oral and injectable treatments. The price of the injectable version is expected to be similar to other brands, with a cost of around €400 in Portugal. This development further enhances the accessibility of obesity treatment, providing patients with a range of options to suit their individual needs and preferences.
The introduction of Wegovy tablets in Portugal is a significant milestone in the field of obesity treatment, offering a more patient-friendly and potentially more affordable approach to managing this chronic condition. The oral treatment, with its flexible dosages and controlled increase in dosage, is a welcome addition to the treatment landscape. The company's efforts to lower medication prices and make obesity treatment more accessible are commendable, and the introduction of the oral treatment in Portugal is a positive development for patients seeking effective and convenient weight management solutions.
